Details

Autor(en) / Beteiligte

• Chiuppesi, Flavia
• Zaia, John A.
• Faircloth, Katelyn
• Johnson, Daisy
• Ly, Minh
• Karpinski, Veronica
• La Rosa, Corinna
• Drake, Jennifer
• Marcia, Joan
• Acosta, Ann Marie
• Dempsey, Shannon
• Taplitz, Randy A.
• Zhou, Qiao
• Park, Yoonsuh
• Ortega Francisco, Sandra
• Kaltcheva, Teodora
• Frankel, Paul H.
• Rosen, Steven
• Wussow, Felix
• Dadwal, Sanjeet
• Diamond, Don J.

Titel

Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants

Ist Teil von

• iScience, 2022-08, Vol.25 (8), p.104745-104745, Article 104745

Ort / Verlag

Elsevier Inc

Erscheinungsjahr

2022

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Cell-mediated immunity may contribute to providing protection against SARS-CoV-2 and its variants of concern (VOC). We developed COH04S1, a synthetic multiantigen modified vaccinia Ankara (MVA)-based COVID-19 vaccine that stimulated potent spike (S) and nucleocapsid (N) antigen-specific humoral and cellular immunity in a phase 1 clinical trial in healthy adults. Here, we show that individuals vaccinated with COH04S1 or mRNA vaccine BNT162b2 maintain robust cross-reactive cellular immunity for six or more months post-vaccination. Although neutralizing antibodies induced in COH04S1- and BNT162b2-vaccinees showed reduced activity against Delta and Omicron variants compared to ancestral SARS-CoV-2, S-specific T cells elicited in both COH04S1- and BNT162b2-vaccinees and N-specific T cells elicited in COH04S1-vaccinees demonstrated potent and equivalent cross-reactivity against ancestral SARS-CoV-2 and the major VOC. These results suggest that vaccine-induced T cells to S and N antigens may constitute a critical second line of defense to provide long-term protection against SARS-CoV-2 VOC. [Display omitted] •COH04S1 and BNT162b2 vaccine-elicited cellular immunity sustained for six months•Neutralizing antibodies with reduced activity against Delta and Omicron variants•Spike- and nucleocapsid-specific T cells maintain cross-reactivity to variants•Vaccine-induced T cells may provide long-term protection against SARS-CoV-2 Health sciences; Immunology; Immune response; Virology